you are here:

Glenmark Pharma Ltd.

BSE: 532296 | NSE: GLENMARK |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE935A01035 | SECTOR: Pharmaceuticals

BSE Live

Nov 25, 16:00
466.40 -14.15 (-2.94%)
Volume
AVERAGE VOLUME
5-Day
92,461
10-Day
97,923
30-Day
116,156
175,148
  • Prev. Close

    480.55

  • Open Price

    483.15

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Nov 25, 15:59
466.30 -14.20 (-2.96%)
Volume
AVERAGE VOLUME
5-Day
1,803,272
10-Day
1,903,827
30-Day
2,759,239
2,611,985
  • Prev. Close

    480.50

  • Open Price

    484.00

  • Bid Price (Qty.)

    466.30 (620)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Glenmark

  • Nov 24, 2020 19:10 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Credit Rating

    Sub:- Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 - S&P Global Ratings With reference to the subject mentioned above, kindly find enclosed rating research update issued by S&P Global Ratings for your reference.

  • Nov 23, 2020 12:00 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure

  • Nov 20, 2020 17:49 Source: BSE

    Glenmark Pharma - Intimation Under The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended ("SEBI LODR")

    We wish to inform you that Glenmark Pharmaceuticals Limited (''Company'') has issued a notice of optional redemption to the holders of U.S. $200 million 4.5% Senior Notes due 2021 (''Notice'') listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith. Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the Notice. We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.

  • Nov 11, 2020 8:57 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Glenmark Pharmaceuticals receives ANDA approval for Tacrolimus Capsules USP, 0.5 mg, 1 mg and 5 mg

  • Nov 06, 2020 21:02 Source: BSE

    Glenmark Pharma - Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended September 30, 2020

    Pursuant to Regulations 30 and 33 of the SEBI LODR, 2015, we wish to inform you that Board has today at its meeting approved the Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020. The said meeting of the Board commenced at 5.00 p.m. and concluded at 8.45 p.m. The copy of the said results together with Management Discussion & Analysis, Press Release and Limited Review Report of the Auditors is enclosed herewith. These are also being made available on the website of the Company at www.glenmarkpharma.com.

  • Oct 28, 2020 22:01 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed Notice of the Board Meeting published in newspapers viz. the Free Press Journal and Navshakti on October 28, 2020.

  • Oct 28, 2020 20:09 Source: BSE

    Glenmark Pharma - Announcement under Regulation 30 (LODR)-Cessation

    Pursuant to Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have to inform you that Mr. Milind Sarwate (DIN: 00109854) was appointed as Non Executive Independent Director of the Company for a term of Five Years commencing from October 29, 2015 to October 28, 2020. Mr. Milind Sarwate, has conveyed that due to his pre-occupation, he would be unable to continue as Director on the Board of the Company post completion of his term as Non-Executive Independent Director with effect from close of business hours on October 28, 2020. Hence, Mr. Milind Sarwate ceases to be a Director of the Company from close of business hours on October 28, 2020.

  • Oct 27, 2020 17:41 Source: BSE

    Glenmark Pharma - Closure of Trading Window

    We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Friday, November 6, 2020, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.

  • Oct 27, 2020 17:38 Source: BSE

    Glenmark Pharma - Board Meeting Intimation for The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2020

    GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2020 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Second Quarter and Half Year ended September 30, 2020. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from September 30, 2020 to November 8, 2020 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Second Quarter and Half Year ended September 30, 2020.

  • Oct 19, 2020 18:00 Source: BSE

    Glenmark Pharma - Shareholding for the Period Ended September 30, 2020

    Glenmark Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2020. For more details, kindly Click here

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Nov 06, 2020
Remark : Quarterly Results